Long-term efficacy of brodalumab in ustekinumab-responsive patients with moderate-to-severe psoriasis

被引：0
|
作者：
Green, Lawrence [1 ]
Hsu, Sylvia [2 ]
Papp, Kim A. [3 ]
Rastogi, Shipra [4 ]
Pillai, Radhakrishnan [5 ]
Israel, Robert J. [6 ]
机构：
[1] George Washington Univ, Sch Med, Washington, DC 20052 USA
[2] Temple Univ, Sch Med, Philadelphia, PA 19122 USA
[3] Prob Med Res, Waterloo, ON, Canada
[4] Ortho Dermatol, Bridgewater, MA USA
[5] Dow Pharmaceut Sci, Petaluma, CA USA
[6] Valeant Pharmaceut North Amer, Bridgewater, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
6832
引用
收藏
页码：AB181 / AB181
页数：1
相关论文
共 50 条
  • [21] Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis
    Rich, P.
    Feldman, S.
    Vender, R.
    Ortonne, J. P.
    Rustin, M.
    Kunynetz, R.
    Yeilding, N.
    Fakharzadeh, S.
    Li, S.
    Prinz, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 18 - 18
  • [22] Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3
    Reich, K.
    Iversen, L.
    Puig, L.
    Lambert, J.
    Mrowietz, U.
    Saday, K. Kaplan
    Warren, R. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1275 - 1283
  • [23] Rapid clinical response predicts consistent long-term response in patients with moderate-to-severe psoriasis: Ixekizumab vs. ustekinumab
    Augustin, Matthias
    Gooderham, Melinda
    Amato, David
    Gallo, Gaia
    See, Kyoungah
    McKean-Matthews, Missy
    Burge, Russel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB113 - AB113
  • [24] Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    Papp, K. A.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. -C.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (04) : 844 - 854
  • [25] Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
    Griffiths, Christopher E. M.
    Strober, Bruce E.
    van de Kerkhof, Peter
    Ho, Vincent
    Fidelus-Gort, Roseanne
    Yeilding, Newman
    Guzzo, Cynthia
    Xia, Yichuan
    Zhou, Bei
    Li, Shu
    Dooley, Lisa T.
    Goldstein, Neil H.
    Menter, Alan
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (02): : 118 - 128
  • [26] COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
    Schembri, J.
    Barbeau, M.
    Gaudet, V
    VALUE IN HEALTH, 2018, 21 : S425 - S425
  • [27] Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis
    Toth, Darryl P.
    Papp, Kim
    Gratton, David
    DERMATOLOGIC THERAPY, 2008, 21 : S6 - S14
  • [28] Long-Term Safety and Efficacy of Etanercept in Patients with Moderate-to-Severe Psoriasis: 5-Years Data Experience
    Conti, Andrea
    Galdo, Giovanna
    Greco, Maurizio
    Borsari, Stefania
    Lasagni, Claudia
    CLINICAL DRUG INVESTIGATION, 2013, 33 : S84 - S86
  • [29] CAVEATS IN INTERPRETING AND COMPARING LONG-TERM EFFICACY IN BIOLOGIC STUDIES FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Langley, Richard G.
    Egeberg, Alexander
    Gooderham, Melinda
    Bissonnette, Robert
    Ringuet, Julien
    Kalia, Sunil
    Park-Wyllie, Laura
    Abbarin, Nastaran
    Tran, Diana
    Zara, Anthony
    Yang, Ya-Wen
    Strober, Bruce
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [30] Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
    Igarashi, Atsuyuki
    Kato, Takeshi
    Kato, Mai
    Song, Michael
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2012, 39 (03): : 242 - 252
12345